Filing Flows › Myriad Genetics (MYGN) › Q2 2026
Myriad Genetics (MYGN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 31, 2026
Myriad Genetics (MYGN) reported revenue of $191M for the second quarter 2026 (Q2 2026), -11% from a year earlier and -5% from the quarter before. Operating margin was -20.4%, net loss $43.2M (22.7% of revenue).
Myriad Genetics, Q2 2026: revenue $191M (-10% year over year), operating margin -20.4%, net loss $43.2M, operating cash flow −$8.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $191M | -5% | -11% |
| Operating profit | −$38.9M | — | — |
| Net earnings | −$43.2M | — | — |
| Operating cash flow | −$8.3M | — | — |
What changed
Revenue was $190.7M in Q2 2026, down 11% year over year and down 5% from the previous quarter. Cancer Care Continuum was the largest line at 60% of revenue. Cancer Care Continuum lost $13.6M year over year (down 11%), 61% of the total change.
Gross margin was 66.6%, down 4.6 points from Q2 2025. Operating costs exceeded revenue by $38.9M, an operating margin of -20.4%. Operating expenses fell 66% while revenue fell 11%. The fastest-growing cost line was Sales & marketing (+16%). The quarter ended with a net loss of $43.2M, wider than the previous quarter's $34.1M loss.
Operating cash flow was −$8.3M. Non-cash charges added back $12.5M of depreciation and amortization and $7.2M of share-based compensation. Working capital and other items added $15.2M. Capital expenditures of $2.1M exceeded it, leaving free cash flow of −$10.4M.
Questions
What was Myriad Genetics' revenue in the second quarter 2026?
Myriad Genetics (MYGN) reported revenue of $191M for the second quarter 2026 (Q2 2026), -11% from a year earlier and -5% from the quarter before.
Was Myriad Genetics profitable in the second quarter 2026?
Operating loss was $38.9M (-20.4% of revenue) and net loss $43.2M.
Source: Myriad Genetics 10-Q on SEC EDGAR.